Monday, 10 February 2020

Global Surgical Sealants and Adhesives Market Set for Big Growth - Foresight by 2023

Growing prevalence and incidence of various disorders, growth in the number of accidents, and growth in the number of surgeries are expected to drive the growth of market. According to the Centers for Disease Control and Prevention (CDC), each year around 630,000 Americans die from heart disease. On other hand, lack of reimbursements policy; and extensive clinical data requirements for launching products can restrain the market growth over the assessment period.
Global Surgical Sealants and Adhesives Market size is expected to grow significantly over the forecast period. It is anticipated that the market held a market value of USD 2.12 billion in 2017 and is projected to grow at a CAGR of 9.3% over the forecast period.
Regional Analysis
Geographically, the Americas is expected to dominate the global surgical sealants and adhesives market share owing to the presence of well-developed healthcare sector, growing prevalence and incidence of various disorders, growth in the number of accidents, and growth in the number of surgeries. Europe is expected to hold the second largest position in the global surgical sealants and adhesives market owing to the growing prevalence of chronic diseases coupled with increasing adoption of new technologies. Asia-Pacific is expected to be the fastest growing market owing to the large population base of the diabetic patients and increasing developments in healthcare segment. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global surgical sealants and adhesives market.      
Segmentation
The global surgical sealants and adhesives market has been segmented into product, indication, application, and end user.
Based on product, has been segmented into natural/biological sealants and adhesives and synthetic and semisynthetic sealants and adhesives. The natural/biological sealants and adhesives and synthetic segment is accounted for the largest share segment of the market in 2017.
The market, by indication, has been segmented into surgical hemostasis, tissue sealing, and tissue engineering.
The market, by application, has been segmented into general surgeries, cardiovascular surgeries, central nervous system surgeries, orthopedic surgeries, urological surgeries, and others.
Key players
Bard, Inc. (US), Johnson & Johnson (UK), Baxter International, Inc. (US), Medtronic plc (US), B. Braun Melsungen AG (Germany), Cohera Medical, Inc. (US), Sanofi Group (France), Sealantis, Ltd (Israel), Vivostat A/S (Denmark), and Ocular Therapuetix, Inc. (US) are some of the key players in the global surgical sealants and adhesives market.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Animal Genetics Industry Growth, Trends and Forecast Till 2023 By MarketResearchFuture.com

Global Particle Therapy Market: Information by Type (Proton Therapy & Heavy Ion Therapy), Product & Service (Products & Others), Cancer Type (Prostate, Lung), System (Multi-Room & Single Room), Application (Treatment & Research) —  Forecast till 2023
Market Scenario:
Particle therapy is one of the world's most advanced areas of external beam radiation therapy applied to oncology. This technique saves healthier radiation tissue better than conventional photon therapy. These particles have more favorable physical intrinsic properties that reduce the intake dose to approximately 50% of the dose in a clinically relevant target.
The Global Particle Therapy Market is accounted for USD 790.45 million in 2017 and expected to register 9.1% CAGR during the forecast period (2018–2023). 
The rising prevalence of cancer population, low risk of treatment induced disorders, potential for retreatment owing to low radiation dose, and rising number of particle therapy centers across the world are expected to drive the growth of the Particle therapy market share. Moreover, rising R&D spending and aggressive strategies adopted by the top players such as new product launches are contributing to the growth of the market. For instance, in December 2017, Advanced Oncotherapy plc announced that it secures the fresh funding of USD 46.75 million from which USD 37.5 million of funds coming from a new Chinese investor. The lack of adequate reimbursement policy and high costs involved in the establishment of these centers may hamper the growth of the particle therapy market size during the assessment period.
Regional Analysis:
The market is likely to dominate by Americas during the forecast period owing to the increasing prevalence of cancer patients, rising government focused towards establishment of particle therapy centers for treatment, and well-established healthcare sector in the region. The European market is expected to be the second-largest due to government funding and support of the healthcare sector, coupled with increasing research and development. Moreover, the particle therapy market APAC is anticipated to be the fastest-growing during the forecast period owing to technological development, increasing adoption of advance treatment from developed countries, and favorable government initiatives for healthcare facilities. The market in the Middle East & Africa is likely to account for the smallest share of the global particle therapy market.
Segmentation:
The Global Particle Therapy Market has been segmented on the basis of type, product & service, cancer type, system, and application.On the basis of type, the market has been classified as proton therapy and heavy ion therapy. The market, by product and services, has been segmented into products and services. Products are further segmented into cyclotrons, synchrotrons, and synchrocyclotrons. Based on cancer type, the market has been segmented into prostate cancer, lung cancer, pediatric cancer, head and neck cancer, breast cancer, and others. The market, by system, has been segmented into multi-room systems and single-room systems. On the basis of application, the market has been classified as treatment applications and research applications. The pediatric cancer segment is expected to hold the largest market share of the particle therapy market, by cancer type, during the forecast period. Also, research applications to register the highest CAGR in the global particle therapy market during the forecast period.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The particle therapy market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European particle therapy market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The particle therapy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The particle therapy market in the Middle East & Africa has been segmented into the Middle East and Africa. 
Key Players
Some of the key players in the global particle therapy market are Advanced Oncotherapy PLC., Danfysik A/S, Hitachi, Ltd., Ion Beam Applications Sa (IBA), Mevion Medical Systems, Inc., Optivus Proton Therapy, Inc., Protom International, Inc., Provision Healthcare, LLC, Sumitomo Heavy Industries, Ltd., Varian Medical Systems, Inc.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Global Particle Therapy Market 2019 Analysis by Manufacturers, Latest Trends, Competitive Landscape and Strategies

Global Particle Therapy Market: Information by Type (Proton Therapy & Heavy Ion Therapy), Product & Service (Products & Others), Cancer Type (Prostate, Lung), System (Multi-Room & Single Room), Application (Treatment & Research) —  Forecast till 2023
Market Scenario:
Particle therapy is one of the world's most advanced areas of external beam radiation therapy applied to oncology. This technique saves healthier radiation tissue better than conventional photon therapy. These particles have more favorable physical intrinsic properties that reduce the intake dose to approximately 50% of the dose in a clinically relevant target.
The Global Particle Therapy Market is accounted for USD 790.45 million in 2017 and expected to register 9.1% CAGR during the forecast period (2018–2023). 
The rising prevalence of cancer population, low risk of treatment induced disorders, potential for retreatment owing to low radiation dose, and rising number of particle therapy centers across the world are expected to drive the growth of the Particle therapy market share. Moreover, rising R&D spending and aggressive strategies adopted by the top players such as new product launches are contributing to the growth of the market. For instance, in December 2017, Advanced Oncotherapy plc announced that it secures the fresh funding of USD 46.75 million from which USD 37.5 million of funds coming from a new Chinese investor. The lack of adequate reimbursement policy and high costs involved in the establishment of these centers may hamper the growth of the particle therapy market size during the assessment period.
Key Players
Some of the key players in the global particle therapy market are Advanced Oncotherapy PLC., Danfysik A/S, Hitachi, Ltd., Ion Beam Applications Sa (IBA), Mevion Medical Systems, Inc., Optivus Proton Therapy, Inc., Protom International, Inc., Provision Healthcare, LLC, Sumitomo Heavy Industries, Ltd., Varian Medical Systems, Inc.
Regional Analysis:
The market is likely to dominate by Americas during the forecast period owing to the increasing prevalence of cancer patients, rising government focused towards establishment of particle therapy centers for treatment, and well-established healthcare sector in the region. The European market is expected to be the second-largest due to government funding and support of the healthcare sector, coupled with increasing research and development. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to technological development, increasing adoption of advance treatment from developed countries, and favorable government initiatives for healthcare facilities. The market in the Middle East & Africa is likely to account for the smallest share of the global particle therapy market.
Segmentation:
The Global Particle Therapy Market has been segmented on the basis of type, product & service, cancer type, system, and application.On the basis of type, the market has been classified as proton therapy and heavy ion therapy. The market, by product and services, has been segmented into products and services. Products are further segmented into cyclotrons, synchrotrons, and synchrocyclotrons. Based on cancer type, the market has been segmented into prostate cancer, lung cancer, pediatric cancer, head and neck cancer, breast cancer, and others. The market, by system, has been segmented into multi-room systems and single-room systems. On the basis of application, the market has been classified as treatment applications and research applications. The pediatric cancer segment is expected to hold the largest market share of the particle therapy market, by cancer type, during the forecast period. Also, research applications to register the highest CAGR in the global particle therapy market during the forecast period.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The particle therapy market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European particle therapy market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The particle therapy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The particle therapy market in the Middle East & Africa has been segmented into the Middle East and Africa. 

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

International Hemorrhoids Treatment Market and Prominence 2023 on Consumer Needs, Revenue, Pricing strategy and Growth Rate

Global Hemorrhoids Treatment market research report, by Treatment type (drugs, non-surgical procedures, surgical procedures), Route of administration (oral, topical agents) Distribution channel (retail pharmacies) – Forecast till 2023
Market Scenario:
The prevalence of hemorrhoids is found particularly between the age of 45 and 65, both in men and women. However, only a small percentage of the affected population seek any form of medical treatment like medication or surgery and instead opt for relief pills purchased from pharmacies.
Hemorrhoid is a highly uncomfortable disorder which is also known as piles. The condition is so subtle yet dangerous that most people under the age of fifty are unaware of the same. Hemorrhoids are inflamed, swollen veins situated in the anal canal and causes a strong sense of irritation in the form of both pain and itchiness. Patients who suffer from the same condition seek relief from a variety of products, boasting both negatives and positives. Direct products like wipes, creams, pads, and suppositories are highly effective at offering temporary period of relief. However, it is not effective enough for permanent treatments.
According to the latest report by the team of Market Research Future (MRFR), the global hemorrhoids treatment market size is expected to grow at a decent rate of 7.1% during the forecast period of 2018 to 2023. The market growth is influenced by numerous factors like the increasing prevalence of lifestyle-based diseases, growing demand for treatment, an increasing demand for reducing infections & complications relating to hemorrhoids, and an increasing number of surgeries. The growing old-age population is also one of the key contributors to the global demand for hemorrhoids treatment. However, lack of awareness and hesitancy towards medical treatment due to the feeling of embarrassment stands out as a key constraint to the growth of the global market.
Market Segmentation
The global hemorrhoids treatment market segmentation is based in terms of route of administration, treatment type, distribution channel, and region.
By treatment type, the market segments into drugs, surgical procedures, and non-surgical procedures. The drugs segment is further segmented into NSAIDs, laxatives, and herbals. The non-surgical procedures narrows down into cryotherapy, band litigation, and sclerotherapy.
By route of administration, the market divides into oral and topical agents.
By distribution channel, the market includes hospital pharmacies, retail pharmacies, online pharmacies, and others.
Regional Analysis
The regional segmentation of the global hemorrhoids market covers four major regions globally, namely Asia Pacific, Europe, the Americas, and the Middle East & Africa.
The Americas hold the maximum share of the market as per the global standings. The dominance of the region can be attributed to the huge patient population, high expenditure in the healthcare sector, and a well-established technology. The regional market for hemorrhoids treatment is expected to continue its dominance in the forthcoming years.
Europe accounts for the second largest market globally following the Americas. The European region is segmented into key regions, namely Western and Eastern Europe. The Western European region consists of countries like the UK, Germany, and France. Factors that primarily push the market in this region are the lack of any physical exercise, sedentary lifestyle, obesity, alcoholism, poor fiber intake in diet, etc.
Asia Pacific is slated to be the fastest growing regions in hemorrhoids. The growth in this region can be attributed to factors like the increasing demand for better diagnostic devices, rapidly improving technologies, better and safe therapeutic approach, and the presence of a massive talent pool.
Competitive Landscape
The global hemorrhoids treatment market holds a number of key players like Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company, Abbott Laboratories, Boston Scientific Corporation, GlaxoSmithKline, Pfizer Inc., AstraZeneca PLC, CONMED Corporation, Taro Pharmaceuticals Inc., Astra Zeneca, Olympus Corporation, Cook Medical, Glenmark Pharmaceuticals Bayer AG, Teva Pharmaceutical Industries Ltd, and others.
13th March 2019, Organization de Scalene announced recently the launch of Cryocure. Cryocure is an affordable medical device that is used to treat piles without any need for surgery.
8th April 2019, Trifecta Pharmaceuticals, one of the leading developers, distributors, and manufacturers of specialty OTC topical creams, gels, and ointments announced today about its distribution partnership with Walmart. The move will see Mayinglong, a hemorrhoid treatment ointment, being available on the shelves of the leading departmental store.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Immune Thrombocytopenia (ITP) Market Worldwide Key Players Forecasts by Revenue, Growth Rate Till 2023

Market Scenario:
Rising prevalence of immune thrombocytopenia (ITP) worldwide has fueled the demand for ITP therapeutics. Increased government effort to improve healthcare infrastructure in countries such as India, China and Brazil has reflected favorably on the global ITP market. In addition, increased focus on development of novel drugs and therapeutics is also having a positive impact on the market. Autoimmune diseases, chronic infections, medications, pregnancy, and certain cancers are common secondary triggers of ITP.
The Global Immune Thrombocytopenia Market size is projected to surpass a valuation of USD 2,300 Mn by 2023, reflecting a compound annual growth rate of 5.78% between 2018 and 2023.
The report includes a discussion on several key market elements. The scope of the discussion also covers different ITP treatments that are currently available such as intravenous immunoglobulins, thrombopoietin receptor agonists and corticosteroids among other. It also covers revenue analysis of major end-users of immune thrombocytopenia, which covers hospitals and clinics, specialty centers, and research and academic institutes.  A detail analysis of the various sub-markets across key region of the world is also available in the report.
Historical market trends, market dynamics, forecast, market value by region as well as by segmentation, country-level analysis for each market segment, key player’s market share analysis and market factor analysis which covers supply chain and Porter’s five forces analysis of the market
Competitive Landscape:
CSL Limited, Amgen Inc., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Rigel Pharmaceuticals, Inc., Shionogi Inc., Dova Pharmaceuticals, Novartis AG, Jiangsu Hengrui Pharmaceutical Co., Ltd., Shire and Ligand Pharmaceuticals, Inc.
Research Methodology:
The research methodology envelops the range and depth of markets and industries that ensures the best outlooks are presented. The methodology successfully combines primary and secondary research methods to present exclusive and pertinent content that can aid in well-versed decision making. The different advances in markets are uniquely included in the reports by employing top-down and bottom-up approaches. Insightful data, advantageous scenarios, and outline of the emerging markets make for a complete and astute guide into the beat of the market. Also, the consistency levels of our reports offer our users adept intelligence that can shape the base of strategies they devise to gain the preferred market portions and hold & enhance their current customer base in several geographies.   
Segmental Analysis:
The segmental analysis of the global ITP market is based on type, treatment, end-user and region. By type, the market has been segmented into chronic immune thrombocytopenia and acute immune thrombocytopenia. In 2017, the chronic immune thrombocytopenia segment for 85% share of the global market. During the forecast period, the segment is projected to witness a CAGR of 5.94% and reach a valuation of USD 2,036.9 Mn. This can be attributed to factors such as rising incidence rates, approval of targeted treatments, increase in risk factors, use of prior medications, and increase occurrence of secondary hematological disorders.
On the basis of the treatment, the market has been segmented into intravenous immunoglobulins, corticosteroids, thrombopoietin receptor agonists, and others.  In 2017, the corticosteroids segmented represented 40% share of the global ITP market in terms of value. The segment is likely to surge at a CAGR of 5.57% during the assessment period. Corticosteroids are a class of steroid hormones that are commonly used in ITP therapies.
On the basis of end-user, the market has been segmented into hospitals and clinics, specialty centers, research and academic institutes, and others. The hospitals & clinic segment currently commands for close to 38% market share and is projected to capture an impressive CAGR of 6.22% during the review period.
Regional Outlook: 
On the basis of region, the Global ITP market is segmented into Americas, Europe, Asia Pacific (APAC) and the Middle East & Africa (MEA). Of these, the Americas accounted for 43.3% market share in 2017. The Americas is expected to spearhead the global ITP market throughout the assessment period. This is primarily owing to the increasing prevalence rates coupled with the availability of treatment options and presence effective reimbursement policies. According to the National Organization for Rare Disorders (NORD), the prevalence of immune thrombocytopenia among adults in the US is estimated to be 3.3 per 100,000 adults/year. In addition, Americas is expected to remain an important market for ITP during the assessment period. Americas is followed by Europe and Asia-Pacific respectively. In Europe, factors such as favorable government policies and high healthcare expenditure is supporting the growth of the market. At the same time, presence of advanced healthcare infrastructure is providing an impetus to the market in Europe. The region is likely to remain its second spot over 2023. In Asia Pacific, increased efforts towards improving healthcare services and rising level of awareness among people is anticipated to drive the market’s growth in APAC in the forthcoming years.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Bone Growth Stimulator Market rise with magnifying growth rate | Forecast by 2023

Market Scenario:
Global Bone Growth Stimulator Market held a market value of USD 1,213 million in 2017 and is projected to grow at a CAGR of 5.86% over the forecast period. Bone Growth Stimulators are devices that are used to boost the healing process during the treatment of the ailments such as spinal fixation, orthopedic fixation, bone fractures and many other. Bone Growth Stimulator enhances the healing process by stimulating the production of new cells, which will allow your fracture to heal considerably faster. This is a perfect approach when you want to get back on your feet quickly. Besides that, one major advantage is surgical operation can be prevented when this approach is used during treatment. Bone growth stimulators have revolutionized the treatment of bone fractures and spinal fusions and are becoming an important tool in the healing process. All these factors contribute to the growth of bone growth stimulator market size.
TOP Key Players:
Some of the prominent players in the global bone growth stimulator market are Arthrex, Inc., Bioventus LLC, Depuy Synthes (A Subsidiary of Johnson & Johnson), DJO Finance LLC, Harvest Technologies (A Terumo BCT Company), Isto Biologics, Medtronic PLC, Orthofix International N.V., Stryker Corporation, and Zimmer Biomet Holdings, Inc..  
Segmentation: Global Bone Growth Stimulator Market has been segmented into product, application and end user.Based on products, the market has been segmented into, bone growth stimulation devices, bone morphogenetic proteins, platelet-rich plasma, and others. The bone growth stimulation devices segment is further segmented into, external bone growth stimulators, implanted bone growth stimulators, and ultrasonic bone growth stimulators among which external bone growth stimulators include pulsed electromagnetic field devices, capacitive coupling devices, and combined magnetic field devices. The bone growth stimulation devices segment is expected to account for the largest share in the global bone growth stimulator market in 2017. This large share is majorly attributed to the wider acceptance of the devices, and better patient compliance as compared to other techniques.
On the basis of application, the market has been segmented into spinal fusion surgeries, delayed union & non-union bone fractures, oral and maxillofacial surgeries, and other. The spinal fusion surgeries segment is expected to account for the largest share in the global bone growth stimulator market in 2017.On the basis of end users, the market has been segmented into hospitals & clinics, home care, academic and research institutes, and others. The hospitals & clinics segment is expected to account for the largest share in the global bone growth stimulator market in 2017. At the same time, the increasing establishments of the home care services in the developed and developing countries has led this segment to grow at the fastest rate during the forecast period.Based on the regions, the market for bone growth stimulator is segmented in to, the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The bone growth stimulator market in the Americas region has further been segmented into North America and South America, where-in the North American market is further divided into the US and Canada.
European bone growth stimulator market has been segmented into Western Europe and Eastern Europe where-in Western Europe region is further divided into Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The bone growth stimulator market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bone growth stimulator market in the Middle East & Africa has been segmented into regions such as the Middle East and Africa.
Regional Analysis:
Geographically, the Americas is anticipated to dominate the global bone growth stimulator market owing to the rising prevalence of the orthopaedic and spinal ailments such as bone fractures, and spinal damage among others. The development of the better therapeutic approaches and advanced treatment procedures have affected the growth of the American market in a positive way. Moreover, increasing rate of the spinal fusion procedures, growing patient population for the orthopaedic fixation procedures, high awareness among American population, high disposable income, are some of the many factors that drive the growth of the bone growth stimulator market in this region.
Europe is expected to hold the second largest market share in the global bone growth stimulator market. The market growth in this region is majorly attributed to the increasing government support for the device manufacturers. Geographical expansion of companies has led to the wider reach of the medical products and services which has brought a huge change in terms of the acceptance and implementation of the new products as well as procedures. Similarly, Asia-Pacific region has observed a rapid growth in the bone growth stimulator market owing to the development in the medical sector in developing countries like India and China. Moreover, increase in government funding for healthcare, rising R&D expenditure, and growing number of medical device companies in the region has led to its fastest growth during the forecast period. The Middle East and Africa region is anticipated to show minor growth opportunities in the bone growth stimulator market during the forecast period.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

ELISpot and FluoroSpot Assay Market Financial Overview, SWOT Analysis, Key Development and Forecasts Till 2023

Market Scenario:
ELISpot and FluoroSpot assays are techniques which are used to assess the antibody reactivity at the cellular level. They are extensively used by hospitals as well as research institutes for early detection of various diseases, most commonly for tuberculosis or viral infection. FluoroSpot assay is an adaptation of the ELISpot assay and has gained widespread acceptance. Market Research Future (MRFR) has extensively studied the patterns and trends governing the global ELISpot and FluoroSpot assay market forecast between 2018-2023 in a detailed report. MRFR has asserted that the market is likely to reach USD 287 Mn at a splendid CAGR of 16.2% over the forecast period. The market stood at USD 135 Mn in 2017.
ELISpot and FluoroSpot assays are outstandingly sensitive and are easy to perform due to which they find extensive application in research studies concerning vaccine development, allergies, cancer, and other research purposes. The surge in the incidence rate of chronic diseases has been instrumental in the growth of the market. Increasing disease burden necessitate the development of vaccines which induce demand for ELISpot and FluoroSpot assays. Additionally, the growing occurrence of oncological diseases has further boosted the market growth. ELISpot and FluoroSpot Market Trends and Technological advances in techniques have resulted in increased sensitivity, robustness, and ease of performance which has increased the adoption rate of these techniques. Other factors motivating growth within the market include an increase in a number of clinical trials and increasing healthcare expenditure across the globe. However, the growth of the market might be hindered by factors such as lack of techniques with adequate knowledge to perform these tests and the availability of alternative detection technologies.
Key players:
Some of the key players in the global ELISpot and FluoroSpot Assay market are Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), and Abcam (UK)Bio-Techne (US), Autoimmun Diagnostika (Germany), Biotech Investissement (France), Lophius Biosciences (Germany), and U-CyTech (Netherlands), and Others.
Segmentation:
The Global ELISpot and FluoroSpot Assay Market is segmented on the basis of product, application, and end-user. The ELISpot and FluoroSpot Assay market, by product is categorised into various assay kit, analyzer, ancillary products. The assay kit is sub-segmented into T Cell assay and B Cell assay. On the basis of application, the market is segmented into transplant, vaccines development, clinical trials, cancer treatment. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centres, diagnostic centres, research centers, and others.
Regional Analysis:
Europe stood second largest in the ELISpot and FluoroSpot Assay market owing to the increasing number of pharmaceutical companies, rising in the development of innovative vaccines for the treatment of various viral diseases. The growing funding from government and private agencies for drug development also support the ELISpot and FluoroSpot Assay market in this region.  Asia-Pacific was estimated to be the fastest growing region for the global ELISpot and FluoroSpot Assay market in 2017. The market is expected to witness growth owing to the rising prevalence of viral infection, increasing geriatric population in this region and growing demand for ELISpot and FluoroSpot Assay in research field.
The Middle East and Africa holds the least share in the global ELISpot and FluoroSpot Assay market due to the presence of low health expenditure, lack of skilled technicians and less pharmaceutical company in this region. However, the market is expected to witness growth due to increasing research & development in the Middle East.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)